Bayer's Eylea shows pandemic resilience, but major China price cut drags on business

Like many of its peers, Bayer was hurt by pandemic-related business slowdowns last quarter. As patients canceled or postponed doctor’s visits and non-urgent treatments during COVID-19, the company suffered from declines in its women’s health and ophthalmology departments. And the situation was only worsened by a newly implemented price cut in China.